# Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

> **NCT00012064** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lisata Therapeutics, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** therapeutic autologous dendritic cells

## Key facts

- **NCT ID:** NCT00012064
- **Lead sponsor:** Lisata Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00012064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00012064, "Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00012064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*